Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + venetoclax + azacitidine in RARA-positive AML ineligible for induction
2021-003910-38Phase 2Active
- Sponsor
- Syros Pharmaceuticals
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tamibarotene in acute myeloid leukemia (AML), sponsored by Syros Pharmaceuticals. Primary endpoint: Primary endpoints - Part 1. Started Sep 2021; status: active.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-003910-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003910-38.